{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:13:29Z","timestamp":1790748809280,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer-induced cachexia, characterized by muscle wasting, is a lethal metabolic syndrome with undefined etiology. Current consensus is that multiple factors contribute to cancer-induced muscle wasting, and therefore therapy requires combinational strategies. Here, we show that Toll-like receptor 4 (TLR4) mediates cancer-induced muscle wasting by directly activating muscle catabolism as well as stimulating an innate immune response in mice bearing Lewis lung carcinoma (LLC), and targeting TLR4 alone effectively abrogate muscle wasting. Utilizing specific siRNAs we observed that LLC cell-conditioned medium (LCM)-treated C2C12 myotubes underwent a rapid catabolic response in a TLR4-dependent manner, including activation of the p38 MAPK\u2212C\/EBP\u03b2 signaling pathway as well as the ubiquitin-proteasome and autophagy-lysosome pathways, resulting in myotube atrophy. Utilizing a reporter cell-line it was confirmed that LCM activated TLR4. These results suggest that LLC-released cachexins directly activate muscle catabolism via activating TLR4 on muscle cells independent of immune responses. Critically, LLC tumor-bearing TLR4<jats:sup>\u2212\/\u2212<\/jats:sup>mice were spared from muscle wasting due to a blockade in muscle catabolic pathways. Further, tumor-induced elevation of circulating TNF\u03b1 and interleukin-6 (IL-6) was abolished in TLR4<jats:sup>\u2212\/\u2212<\/jats:sup>mice. These data suggest that TLR4 is a central mediator and therapeutic target of cancer-induced muscle wasting.<\/jats:p>","DOI":"10.1038\/s41598-017-02347-2","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T10:23:28Z","timestamp":1495016608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways"],"prefix":"10.1038","volume":"7","author":[{"given":"Guohua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhelong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4131-3164","authenticated-orcid":false,"given":"Hongyu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"2347_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell metabolism 16, 153\u2013166, doi:10.1016\/j.cmet.2012.06.011 (2012).","journal-title":"Cell metabolism"},{"key":"2347_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/529156b","volume":"529","author":"K Fearon","year":"2016","unstructured":"Fearon, K. Cachexia: Treat wasting illness on multiple fronts. Nature 529, 156, doi:10.1038\/529156b (2016).","journal-title":"Nature"},{"key":"2347_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1517\/13543784.2014.942729","volume":"23","author":"AM Dingemans","year":"2014","unstructured":"Dingemans, A. M., de Vos-Geelen, J., Langen, R. & Schols, A. M. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs 23, 1655\u20131669, doi:10.1517\/13543784.2014.942729 (2014).","journal-title":"Expert Opin Investig Drugs"},{"key":"2347_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1615\/CritRevOncog.v17.i3.30","volume":"17","author":"JM Argiles","year":"2012","unstructured":"Argiles, J. M., Lopez-Soriano, F. J. & Busquets, S. Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 17, 253\u2013262 (2012).","journal-title":"Crit Rev Oncog"},{"key":"2347_CR5","first-page":"E996","volume":"268","author":"VE Baracos","year":"1995","unstructured":"Baracos, V. E., DeVivo, C., Hoyle, D. H. & Goldberg, A. L. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 268, E996\u20131006 (1995).","journal-title":"Am J Physiol"},{"key":"2347_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai, D. et al. IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice. Cell 119, 285\u2013298, doi:10.1016\/j.cell.2004.09.027 (2004).","journal-title":"Cell"},{"key":"2347_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1096\/fj.02-0759com","volume":"17","author":"YP Li","year":"2003","unstructured":"Li, Y. P. et al. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2\/E220k. FASEB J 17, 1048\u20131057, doi:10.1096\/fj.02-0759com (2003).","journal-title":"FASEB J"},{"key":"2347_CR8","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1038\/emboj.2011.292","volume":"30","author":"G Zhang","year":"2011","unstructured":"Zhang, G., Jin, B. & Li, Y. P. C\/EBPbeta mediates tumour-induced ubiquitin ligase atrogin1\/MAFbx upregulation and muscle wasting. The EMBO journal 30, 4323\u20134335, doi:10.1038\/emboj.2011.292 (2011).","journal-title":"The EMBO journal"},{"key":"2347_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1096\/fj.13-240580","volume":"28","author":"MJ Puppa","year":"2014","unstructured":"Puppa, M. J., Gao, S., Narsale, A. A. & Carson, J. A. Skeletal muscle glycoprotein 130\u2019s role in Lewis lung carcinoma-induced cachexia. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 28, 998\u20131009, doi:10.1096\/fj.13-240580 (2014).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"2347_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1096\/fj.04-2364com","volume":"19","author":"YP Li","year":"2005","unstructured":"Li, Y. P. et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1\/MAFbx in skeletal muscle. FASEB J 19, 362\u2013370, doi:10.1096\/fj.04-2364com (2005).","journal-title":"FASEB J"},{"key":"2347_CR11","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto, A. et al. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 303, E410\u2013421, doi:10.1152\/ajpendo.00039.2012 (2012).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2347_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.12.023","volume":"182","author":"F Penna","year":"2013","unstructured":"Penna, F. et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol 182, 1367\u20131378, doi:10.1016\/j.ajpath.2012.12.023 (2013).","journal-title":"Am J Pathol"},{"key":"2347_CR13","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1096\/fj.201600250RR","volume":"30","author":"KR Bohnert","year":"2016","unstructured":"Bohnert, K. R. et al. Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia. FASEB J 30, 3053\u20133068, doi:10.1096\/fj.201600250RR (2016).","journal-title":"FASEB J"},{"key":"2347_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s13539-014-0141-2","volume":"5","author":"EE Talbert","year":"2014","unstructured":"Talbert, E. E., Metzger, G. A., He, W. A. & Guttridge, D. C. Modeling human cancer cachexia in colon 26 tumor-bearing adult mice. J Cachexia Sarcopenia Muscle 5, 321\u2013328, doi:10.1007\/s13539-014-0141-2 (2014).","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2347_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3945\/ajcn.113.058388","volume":"98","author":"CM Op den Kamp","year":"2013","unstructured":"Op den Kamp, C. M. et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 98, 738\u2013748, doi:10.3945\/ajcn.113.058388 (2013).","journal-title":"Am J Clin Nutr"},{"key":"2347_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jcsm.12005","volume":"6","author":"NA Stephens","year":"2015","unstructured":"Stephens, N. A. et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 6, 53\u201361, doi:10.1002\/jcsm.12005 (2015).","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2347_CR17","doi-asserted-by":"publisher","first-page":"30340","DOI":"10.1038\/srep30340","volume":"6","author":"Z Aversa","year":"2016","unstructured":"Aversa, Z. et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci Rep 6, 30340, doi:10.1038\/srep30340 (2016).","journal-title":"Sci Rep"},{"key":"2347_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature07623","volume":"457","author":"S Kim","year":"2009","unstructured":"Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102\u2013106, doi:10.1038\/nature07623 (2009).","journal-title":"Nature"},{"key":"2347_CR19","doi-asserted-by":"publisher","unstructured":"Hernandez, C., Huebener, P. & Schwabe, R. F. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene, doi:10.1038\/onc.2016.104 (2016).","DOI":"10.1038\/onc.2016.104"},{"key":"2347_CR20","doi-asserted-by":"publisher","unstructured":"Wang, W., Zhang, Y., Yang, L. & Li, H. The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes? Cancer Lett, doi:10.1016\/j.canlet.2016.06.004 (2016).","DOI":"10.1016\/j.canlet.2016.06.004"},{"key":"2347_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/intimm\/dxh186","volume":"17","author":"K Takeda","year":"2005","unstructured":"Takeda, K. & Akira, S. Toll-like receptors in innate immunity. Int Immunol 17, 1\u201314, doi:10.1093\/intimm\/dxh186 (2005).","journal-title":"Int Immunol"},{"key":"2347_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/archotol.133.12.1263","volume":"133","author":"TY Cannon","year":"2007","unstructured":"Cannon, T. Y. et al. The effect of altered Toll-like receptor 4 signaling on cancer cachexia. Arch Otolaryngol Head Neck Surg 133, 1263\u20131269, doi:10.1001\/archotol.133.12.1263 (2007).","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2347_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/01.shk.0000055237.25446.80","volume":"19","author":"CH Lang","year":"2003","unstructured":"Lang, C. H., Silvis, C., Deshpande, N., Nystrom, G. & Frost, R. A. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 19, 538\u2013546, doi:10.1097\/01.shk.0000055237.25446.80 (2003).","journal-title":"Shock"},{"key":"2347_CR24","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1128\/IAI.00286-06","volume":"74","author":"JH Boyd","year":"2006","unstructured":"Boyd, J. H. et al. Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun 74, 6829\u20136838, doi:10.1128\/IAI.00286-06 (2006).","journal-title":"Infect Immun"},{"key":"2347_CR25","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1096\/fj.12-222711","volume":"27","author":"G Zhang","year":"2013","unstructured":"Zhang, G., Lin, R. K., Kwon, Y. T. & Li, Y. P. Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 27, 2893\u20132901, doi:10.1096\/fj.12-222711 (2013).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"2347_CR26","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.4049\/jimmunol.162.7.3749","volume":"162","author":"K Hoshino","year":"1999","unstructured":"Hoshino, K. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162, 3749\u20133752 (1999).","journal-title":"J Immunol"},{"key":"2347_CR27","first-page":"18","volume":"6","author":"B Wiedenmann","year":"2008","unstructured":"Wiedenmann, B. et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 6, 18\u201325 (2008).","journal-title":"J Support Oncol"},{"key":"2347_CR28","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1200\/JCO.1995.13.11.2856","volume":"13","author":"RM Goldberg","year":"1995","unstructured":"Goldberg, R. M. et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 13, 2856\u20132859 (1995).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"2347_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gut.2004.047563","volume":"54","author":"JN Gordon","year":"2005","unstructured":"Gordon, J. N. et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540\u2013545, doi:10.1136\/gut.2004.047563 (2005).","journal-title":"Gut"},{"key":"2347_CR30","doi-asserted-by":"publisher","unstructured":"Braun, T. P. et al. Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J 27, 3572\u20133582, doi:10.1096\/fj.13-230375 (2013).","DOI":"10.1096\/fj.13-230375"},{"key":"2347_CR31","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1073\/pnas.1402714111","volume":"111","author":"WA He","year":"2014","unstructured":"He, W. A. et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci USA 111, 4525\u20134529, doi:10.1073\/pnas.1402714111 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"2347_CR32","doi-asserted-by":"publisher","first-page":"e113259","DOI":"10.1371\/journal.pone.0113259","volume":"9","author":"Y Fujiwara","year":"2014","unstructured":"Fujiwara, Y. et al. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS One 9, e113259, doi:10.1371\/journal.pone.0113259 (2014).","journal-title":"PLoS One"},{"key":"2347_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12032-015-0497-y","volume":"32","author":"C Bilir","year":"2015","unstructured":"Bilir, C., Engin, H., Can, M., Temi, Y. B. & Demirtas, D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol 32, 56, doi:10.1007\/s12032-015-0497-y (2015).","journal-title":"Med Oncol"},{"key":"2347_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcdb.2015.10.039","volume":"54","author":"M Tsoli","year":"2016","unstructured":"Tsoli, M., Swarbrick, M. M. & Robertson, G. R. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol 54, 68\u201381, doi:10.1016\/j.semcdb.2015.10.039 (2016).","journal-title":"Semin Cell Dev Biol"},{"key":"2347_CR35","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1194\/jlr.D029546","volume":"53","author":"S Huang","year":"2012","unstructured":"Huang, S. et al. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res 53, 2002\u20132013, doi:10.1194\/jlr.D029546 (2012).","journal-title":"J Lipid Res"},{"key":"2347_CR36","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1172\/JCI28898","volume":"116","author":"H Shi","year":"2006","unstructured":"Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116, 3015\u20133025, doi:10.1172\/JCI28898 (2006).","journal-title":"J Clin Invest"},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbrc.2006.05.170","volume":"346","author":"MJ Song","year":"2006","unstructured":"Song, M. J., Kim, K. H., Yoon, J. M. & Kim, J. B. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346, 739\u2013745, doi:10.1016\/j.bbrc.2006.05.170 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"2347_CR38","doi-asserted-by":"crossref","unstructured":"Doyle, A., Zhang, G., Abdel Fattah, E. A., Eissa, N. T. & Li, Y. P. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J 25, 99\u2013110, doi:fj.10-164152 (2011).","DOI":"10.1096\/fj.10-164152"},{"key":"2347_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneph.2015.175","volume":"12","author":"J Wada","year":"2016","unstructured":"Wada, J. & Makino, H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol 12, 13\u201326, doi:10.1038\/nrneph.2015.175 (2016).","journal-title":"Nat Rev Nephrol"},{"key":"2347_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.immuni.2007.05.022","volume":"27","author":"Y Xu","year":"2007","unstructured":"Xu, Y. et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27, 135\u2013144, doi:10.1016\/j.immuni.2007.05.022 (2007).","journal-title":"Immunity"},{"key":"2347_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2044-5040-2-20","volume":"2","author":"G Zhang","year":"2012","unstructured":"Zhang, G. & Li, Y. P. p38beta MAPK upregulates atrogin1\/MAFbx by specific phosphorylation of C\/EBPbeta. Skelet Muscle 2, 20, doi:10.1186\/2044-5040-2-20 (2012).","journal-title":"Skelet Muscle"},{"key":"2347_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jcb.21833","volume":"105","author":"M Menconi","year":"2008","unstructured":"Menconi, M., Gonnella, P., Petkova, V., Lecker, S. & Hasselgren, P. O. Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J Cell Biochem 105, 353\u2013364, doi:10.1002\/jcb.21833 (2008).","journal-title":"J Cell Biochem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02347-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02347-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02347-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:18:11Z","timestamp":1692807491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02347-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-02347-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]},"assertion":[{"value":"24 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2273"}}